+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Intravenous Iron Drugs Market Size, Share & Trends Analysis Report By Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • July 2024
  • Region: Global
  • Grand View Research
  • ID: 5415624
Description Jump to:
The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.2% from 2024 to 2030, according to a new report. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2023 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost
  • Iron sucrose held a significant share of the market in 2023. A low rate of severe allergic reactions has increased the adoption rate of these drugs
  • The chronic kidney disease segment held the largest share in 2023, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases
  • North America held the largest regional share in 2023 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players
  • Key players include AbbVie Inc.; AMAG Pharmaceuticals (Covis Pharma); Daiichi Sankyo Company, Ltd.; Sanofi; Vifor Pharma Management Ltd. (CSL); PHARMACOSMOS A/S; Zydus Group

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Market Definitions
1.1.3 Estimates and Forecast Timeline
1.2 Objectives
1.2.1 Objective - 1
1.2.2 Objective - 2
1.2.3 Objective - 3
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Internal database
1.4.3 Secondary Sources
1.4.4 Primary research
1.4.5 Sample size for the study on Intravenous Iron Drugs Market:
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation and Validation
1.7 Market Model
1.7.1 Market study, by Company Market Share
1.7.2 Commodity Flow Analysis
1.7.2.1 Approach 1: Commodity Flow Approach
1.7.2.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
1.7.3 Regional analysis
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
Chapter 2 EXECUTIVE SUMMARY
2.1 Market Snapshot, 2023
2.2 Segment Snapshot
2.3 Competitive Snapshot
Chapter 3 Intravenous Iron Drugs Market - Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.1.2 Related/Ancillary Market Outlook
3.1.2.1 Inflammatory Bowel Disease Treatment Market
3.1.2.2 Anemia Treatment Market
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Increasing prevalence of target diseases
3.2.1.2 Rising prevalence of iron deficiency anemia
3.2.1.3 Advantages of intravenous iron drugs
3.2.2 Market Restraint Analysis
3.2.2.1 Adverse effects associated with iron drugs
3.2.2.2 Increasing approvals of oral iron drugs
3.3 PORTER’S Five Forces Analysis
3.4 PESTLE Analysis
3.5 COVID-19 Impact Analysis
Chapter 4 Intravenous Iron Drugs Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
4.1 Intravenous Iron Drugs Market: Product Movement Analysis
4.2 Intravenous Iron Drugs Market Estimates & Forecast, by Product (USD Million)
4.2.1 Iron Dextran
4.2.2 Iron Sucrose
4.2.3 Ferric Carboxymaltose
4.2.4 Others
Chapter 5 Intravenous Iron Drugs Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
5.1 Intravenous Iron Drugs Market: Application Movement Analysis
5.2 Intravenous Iron Drugs Market Estimates & Forecast, by Application (USD Million)
5.2.1 Chronic Kidney Disease
5.2.2 Inflammatory Bowel Disease
5.2.3 Cancer
5.2.4 Other Diseases
Chapter 6 Intravenous Iron Drugs Market: Regional Estimates and Trend Analysis
6.1 Intravenous Iron Drugs Market: Regional Outlook
6.2 North America
6.2.1 North America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 U.S. Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.2.3 Target Disease Prevalence
6.2.2.4 Market & Competitive Scenario
6.2.2.5 Regulatory Framework
6.2.2.6 Reimbursement Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Canada Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.2.3.3 Target Disease Prevalence
6.2.3.4 Market & Competitive Scenario
6.2.3.5 Regulatory Framework
6.2.3.6 Reimbursement Scenario
6.3 Europe
6.3.1 Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 UK Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2.3 Target Disease Prevalence
6.3.2.4 Market & Competitive Scenario
6.3.2.5 Regulatory Framework
6.3.2.6 Reimbursement Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Germany Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3.3 Target Disease Prevalence
6.3.3.4 Market & Competitive Scenario
6.3.3.5 Regulatory Framework
6.3.3.6 Reimbursement Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 France Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.4.3 Target Disease Prevalence
6.3.4.4 Market & Competitive Scenario
6.3.4.5 Regulatory Framework
6.3.4.6 Reimbursement Scenario
6.3.5 Italy
6.3.5.1 Key Country Dynamics
6.3.5.2 Italy Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.5.3 Target Disease Prevalence
6.3.5.4 Market & Competitive Scenario
6.3.5.5 Regulatory Framework
6.3.5.6 Reimbursement Scenario
6.3.6 Spain
6.3.6.1 Key Country Dynamics
6.3.6.2 Spain Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.6.3 Target Disease Prevalence
6.3.6.4 Market & Competitive Scenario
6.3.6.5 Regulatory Framework
6.3.6.6 Reimbursement Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Denmark Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.7.3 Target Disease Prevalence
6.3.7.4 Market & Competitive Scenario
6.3.7.5 Regulatory Framework
6.3.7.6 Reimbursement Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Sweden Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.8.3 Target Disease Prevalence
6.3.8.4 Market & Competitive Scenario
6.3.8.5 Regulatory Framework
6.3.8.6 Reimbursement Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Norway Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.9.3 Target Disease Prevalence
6.3.9.4 Market & Competitive Scenario
6.3.9.5 Regulatory Framework
6.3.9.6 Reimbursement Scenario
6.3.9.7 Rest of Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)s
6.4 Asia Pacific
6.4.1 Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Japan Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2.3 Target Disease Prevalence
6.4.2.4 Market & Competitive Scenario
6.4.2.5 Regulatory Framework
6.4.2.6 Reimbursement Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 China Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.3.3 Target Disease Prevalence
6.4.3.4 Market & Competitive Scenario
6.4.3.5 Regulatory Framework
6.4.3.6 Reimbursement Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 India Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.4.3 Target Disease Prevalence
6.4.4.4 Market & Competitive Scenario
6.4.4.5 Regulatory Framework
6.4.4.6 Reimbursement Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Australia Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.5.3 Target Disease Prevalence
6.4.5.4 Market & Competitive Scenario
6.4.5.5 Regulatory Framework & Reimbursement Scenario
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.6.3 Target Disease Prevalence
6.4.6.4 Market & Competitive Scenario
6.4.6.5 Regulatory Framework
6.4.6.6 Reimbursement Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.7.3 Target Disease Prevalence
6.4.7.4 Market & Competitive Scenario
6.4.7.5 Regulatory Framework/Reimbursement Scenario
6.4.7.6 Rest of Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Brazil Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2.3 Target Disease Prevalence
6.5.2.4 Market & Competitive Scenario
6.5.2.5 Regulatory Framework
6.5.2.6 Reimbursement Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3.3 Target Disease Prevalence
6.5.3.4 Market & Competitive Scenario
6.5.3.5 Regulatory Framework
6.5.3.6 Reimbursement Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Argentina Intravenous Iron Drugs Market Estimates and forecasts, 2018 - 2030 (USD Million)
6.5.4.3 Target Disease Prevalence
6.5.4.4 Market & Competitive Scenario
6.5.4.5 Regulatory Framework
6.5.4.6 Reimbursement Scenario
6.5.4.7 Rest of Latin America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6 MEA
6.6.1 MEA Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2.3 Target Disease Prevalence
6.6.2.4 Market & Competitive Scenario
6.6.2.5 Regulatory Framework
6.6.2.6 Reimbursement Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3.3 Target Disease Prevalence
6.6.3.4 Market & Competitive Scenario
6.6.3.5 Regulatory Framework
6.6.3.6 Reimbursement Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4.3 Target Disease Prevalence
6.6.4.4 Market & Competitive Scenario
6.6.4.5 Regulatory Framework
6.6.4.6 Reimbursement Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5.3 Target Disease Prevalence
6.6.5.4 Market & Competitive Scenario
6.6.5.5 Regulatory Framework
6.6.5.6 Reimbursement Scenario
6.6.5.7 Rest of MEA Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.1.1 Allergan, Inc.
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 AMAG Pharmaceuticals. Inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Daiichi Sankyo Company, Ltd.
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Sanofi
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 Fresenius Medical Care AG & Co.
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Product benchmarking
7.1.5.4 Strategic initiatives
7.1.6 Vifor Pharma Management Ltd.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Product benchmarking
7.1.6.4 Strategic initiatives
7.1.7 Pharmacosmos A/S
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.8 Rockwell Medical, Inc.
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
Chapter 8 Conclusion
List of Tables
Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 4 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 5 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 8 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 9 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 10 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 11 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 12 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 13 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 14 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 15 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 16 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 17 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 18 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 19 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 20 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 21 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 22 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 23 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 24 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 25 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 26 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 27 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 28 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 29 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 30 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 31 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 32 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 33 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 34 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 35 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 36 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 37 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 38 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 39 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 40 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 41 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 42 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 43 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 44 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 45 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 46 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 47 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 48 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 49 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 50 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 51 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 52 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 53 MEA intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
Table 54 MEA intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 55 MEA intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 56 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 57 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 60 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 61 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
Table 62 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
Table 63 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Intravenous iron drugs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation and validation
Fig. 9 Commodity flow approach
Fig. 10 Market snapshot (USD Million)
Fig. 11 Segment snapshot (product & application)
Fig. 12 Competitive snapshot
Fig. 13 Parent market (USD Billion)
Fig. 14 Market dynamics
Fig. 15 Prevalence of cancer, by type, in 2020 (%)
Fig. 16 Porter’s five forces analysis
Fig. 17 PESTLE analysis
Fig. 18 Intravenous iron drugs market: Product outlook and key takeaways
Fig. 19 Intravenous iron drugs market: Product movement analysis
Fig. 20 Iron dextran market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Iron sucrose market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 FCM market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Intravenous iron drugs market: Application outlook and key takeaways
Fig. 25 Intravenous iron drugs market: Application movement analysis
Fig. 26 Chronic kidney disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Inflammatory bowel disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Incidence of key cancer types that increase the risk of anemia, 2020 (in thousand)
Fig. 30 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Intravenous iron drugs market revenue, by region, 2023 & 2030 (USD Million)
Fig. 32 Regional marketplace: Key takeaways (1/2)
Fig. 33 Regional marketplace: Key takeaways (2/2)
Fig. 34 North America intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Key country dynamics
Fig. 36 U.S. intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Cancer incidence, 2022 and 2030
Fig. 38 Key country dynamics
Fig. 39 Canada intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Cancer incidence, 2018 - 2030
Fig. 41 Europe intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 UK intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Cancer incidence, 2018 - 2030
Fig. 45 Key country dynamics
Fig. 46 Germany intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Cancer incidence, 2018 - 2030
Fig. 48 Key country dynamics
Fig. 49 France intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Cancer incidence, 2018 - 2030
Fig. 51 Key country dynamics
Fig. 52 Italy intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Cancer incidence, 2018 - 2030
Fig. 54 Key country dynamics
Fig. 55 Spain intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Cancer incidence, 2018 - 2030
Fig. 57 Key country dynamics
Fig. 58 Denmark intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Target disease prevalence
Fig. 60 Key country dynamics
Fig. 61 Sweden intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Five most common cancers in Sweden
Fig. 63 Key country dynamics
Fig. 64 Norway intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Number of new cancer cases in 2020, both sexes, all ages
Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Asia Pacific intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Japan intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Number of new cases in 2020, both sexes, all ages
Fig. 71 Key country dynamics
Fig. 72 China intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Cancer incidence, 2018 to 2030
Fig. 74 Key country dynamics
Fig. 75 India intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Cancer incidence, 2018 to 2030
Fig. 77 Key country dynamics
Fig. 78 Australia intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Cancer incidence, 2018 to 2030
Fig. 80 Key country dynamics
Fig. 81 Thailand intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Cancer incidence, 2020 to 2030
Fig. 83 Key country dynamics
Fig. 84 South Korea intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Cancer incidence 2018 to 2030
Fig. 86 Rest of Asia Pacific intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Latin America intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Brazil intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Estimated number of new cancer cases in Brazil
Fig. 91 Key country dynamics
Fig. 92 Mexico intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Estimated number of new cancer cases in Mexico
Fig. 94 Key country dynamics
Fig. 95 Argentina intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Estimated number of new cancer cases in Argentina
Fig. 97 Rest of Latin America intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 MEA intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Key country dynamics
Fig. 100 South Africa intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 101 Cancer prevalence -2018 - 2030
Fig. 102 Key country dynamics
Fig. 103 Saudi Arabia intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Cancer prevalence - 2018 - 2030
Fig. 105 Key country dynamics
Fig. 106 UAE intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 107 Cancer prevalence-2018 - 2030
Fig. 108 Key country dynamics
Fig. 109 Kuwait intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Target disease prevalence
Fig. 111 Rest of MEA intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Market participant categorization
Fig. 113 Company market share analysis, 2023
Fig. 114 Strategic framework

Companies Mentioned

  • Allergan, Inc.
  • AMAG Pharmaceuticals. Inc.
  • Daiichi Sankyo Company, Ltd.
  • Sanofi
  • Fresenius Medical Care AG & Co.
  • Vifor Pharma Management Ltd.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedJuly 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.03 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.62 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Intravenous Iron Drugs Market by Product, Application - Global Forecast 2025-2030 - Product Image

Intravenous Iron Drugs Market by Product, Application - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Intravenous (IV) Iron Drugs - Global Strategic Business Report - Product Image

Intravenous (IV) Iron Drugs - Global Strategic Business Report

  • Report
  • 354 Pages
  • Global
From
Iron Drugs Market by Product, Application - Global Forecast 2025-2030 - Product Image

Iron Drugs Market by Product, Application - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Global IV & Oral Iron Drugs Market - Focused Insights 2024-2029 - Product Image

Global IV & Oral Iron Drugs Market - Focused Insights 2024-2029

  • Report
  • 126 Pages
  • Global
From
Iron Drugs - Global Strategic Business Report - Product Image

Iron Drugs - Global Strategic Business Report

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.